-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion reports new preclinical data for EVX-04 AML therapeutic vaccine ahead of EHA 2026 poster

PUBT·06/11/2026 06:00:50
Listen to the news
Evaxion reports new preclinical data for EVX-04 AML therapeutic vaccine ahead of EHA 2026 poster
  • Evaxion disclosed new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia.
  • Results will be presented June 13, 2026 at the European Hematology Association 2026 Congress in Stockholm.
  • Data showed EVX-04 was expressed and secreted in human cells, supporting immune recognition and activation.
  • Studies indicated the vaccine antigens triggered targeted immune responses across different human immune profiles, leading to tumor-cell killing.
  • Evaxion said it is advancing preclinical work while preparing regulatory filings for clinical testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110200OMX_____CNEWS_EN_GNW1001186932_en) on June 11, 2026, and is solely responsible for the information contained therein.